Plain-English translation of NCT06743126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new personalized cell therapy for melanoma that has progressed despite previous treatment with immunotherapy drugs. Researchers take some of your white blood cells, grow them in the lab to enhance their ability to fight melanoma, and then give them back to you along with supportive medications. The goal is to see whether this approach works better than other standard treatment options.
Many melanoma patients see their cancer stop responding to common immunotherapy drugs like and , leaving them with limited options. This trial is testing whether training a patient's own immune cells to attack melanoma more aggressively could offer a better chance of controlling the disease.
You likely qualify if…
You likely don't qualify if…
If you are in the experimental group, you will first undergo a procedure to collect your white blood cells (leukapheresis). Then you will receive chemotherapy medications for a few days to prepare your body, followed by hospitalization for the infusion of your treated cells. After that, you will receive daily injections of a supportive medication for up to 10 days. If you are in the control group, you will receive one of several standard melanoma treatments chosen by your doctor. Both groups will be monitored closely with regular visits and tests to check how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States